RecruitingNCT00114647
Apheresis to Obtain Plasma or White Blood Cells for Laboratory Studies
Studying Holt-Oram syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Susan L Moir, Ph.D.National Institute of Allergy and Infectious Diseases (NIAID)
- Enrollment
- 3000 target
- Eligibility
- 18-100 years · All sexes
- Timeline
- 1984
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00114647 on ClinicalTrials.govOther trials for Holt-Oram syndrome
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT03895645Connors Protocol for the Management and Use of Stored Human Specimens (Stored Human Specimens)National Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNANCT07352683Open TAP-block in Pediatric Abdominal SurgeryUppsala University
- RECRUITINGNANCT07301489Akershus Cardiac Examination (ACE) 5 StudyUniversity Hospital, Akershus
- RECRUITINGPHASE3NCT07000357A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First EventAstraZeneca
- RECRUITINGPHASE1NCT06995729A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of MigrainePfizer
- RECRUITINGNCT06761105Using Anonymous Data From A Digital Tool for Medical History-Taking To Improve Healthcare ServicesUniversity Hospital Goettingen
- ACTIVE NOT RECRUITINGNCT06735742A Study to Learn About the Safety of TALZENNA for the Treatment of Breast CancerPfizer
- ACTIVE NOT RECRUITINGPHASE2NCT06897748A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated EosinophilsAstraZeneca